PARSIPPANY, N.J., Jan. 27 /PRNewswire/ -- DSM Pharmaceutical Products today announced that they will join the Green Chemistry Institute(R) Pharmaceutical Roundtable (Roundtable) of the American Chemical Society (ACS) as an associate member. The Pharmaceutical Roundtable is a partnership between the ACS Green Chemistry Institute(R) and pharmaceutical companies. The roundtable was founded in 2005 to promote sustainable manufacturing of active pharmaceutical ingredients (APIs) by integrating the principles of green chemistry and engineering into drug discovery and manufacturing. Recently it was decided that companies which are significantly engaged in research and development or manufacturing of intermediates and APIs for the pharmaceutical industry could apply for membership. DSM Pharmaceutical Products is the first such company to join the Roundtable.
Bob Hartmayer, president & CEO of the DSM Pharmaceutical Products business group, commented, “I am proud that DSM’s ambition to play in the top league of sustainable manufacturers is recognized by the Roundtable members. It stimulates us to continue to work with our customers towards new and green synthetic routes for API synthesis; to be the first supplier company to join this roundtable is a real honor.”
Bob Peoples, director of the ACS Green Chemistry Institute(R), comments: “The addition of DSM as our first associate member is a significant development in the expansion of the ACS GCI Pharmaceutical Roundtable. We look forward to working with DSM who brings complementary expertise to support the mission of the Roundtable and will further leverage the excellent work of this dedicated group of leading pharmaceutical companies.”
DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API’s), fermentation, mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticals.com
DSM Pharma Chemicals
DSM Pharma Chemicals is a global provider of custom manufacturing services to the pharmaceutical industry. Including advanced intermediates, registered materials and active pharmaceutical ingredients. Our technologies include biocatalysis, homogeneous catalysis, fermentation and chiral technologies. DSM delivers comprehensive custom manufacturing services to the spectrum of pharmaceutical companies including emerging pharmaceutical companies and large pharmaceutical companies from clinical to commercial manufacturing.
Royal DSM N.V. - The Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM’s products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com
ACS Green Chemistry Institute(R) Pharmaceutical Roundtable
The ACS Green Chemistry Institute(R) Pharmaceutical Roundtable is a partnership between the American Chemical Society’s Green Chemistry Institute and member pharmaceutical companies dedicated to the integration of green chemistry and green engineering in the global pharmaceutical industry. Current members include AstraZeneca, Boehringer-Ingelheim, DSM Pharmaceutical Products, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc, Schering-Plough, and Wyeth. The activities of the Roundtable reflect the joint belief that the pursuit of green chemistry and green engineering is imperative for sustainable business and world environment. The Roundtable focuses on four strategic priorities: informing and influencing the research agenda; defining and delivering tools for innovation; educating leaders; and collaborating globally. More information on the Pharmaceutical Roundtable can be found at www.acs.org/gcipharmaroundtable.
For further information please contact:
DSM Pharmaceutical Products
ACS
Green Chemistry Institute(R)
Pharmaceutical Roundtable
Forward-looking statements
This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.
CONTACT: Dr. Ronald Gebhard, Director Research & Development, DSM
Pharmaceutical Products, Tel:+31 46 4761514, Mob: +31 6 51 72 846,
ronald.gebhard@dsm.com; or ACS Green Chemistry Institute(R) Pharmaceutical
Roundtable, Julie B. Manley, Senior Industrial Coordinator,
+1-815-325-4974, j_manley@acs.org
Web site: http://www.dsm.com/
http://www.dsmpharmaceuticals.com/
